Bio-Rad Laboratories (BIO) Common Equity (2009 - 2026)

Bio-Rad Laboratories (BIO) has reported Common Equity for 18 consecutive years, with $7.2 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Common Equity rose 0.63% year-over-year to $7.2 billion in Q2 2026; TTM through Jun 2026 was $7.2 billion, a 0.63% increase from a year earlier, with the FY2025 full-year figure at $7.5 billion, up 13.46% from the prior year.
• Common Equity was $7.2 billion for Q2 2026 at Bio-Rad Laboratories, up from $6.9 billion in the prior quarter.
• Over five years, Common Equity peaked at $10.2 billion in Q1 2022 and troughed at $6.6 billion in Q4 2024.
• A 5-year average of $8.0 billion and a median of $8.0 billion in 2023 frame the typical range for Common Equity.
• Across the five-year window, Common Equity tumbled 44.71% in 2022 and gained 13.46% in 2025, its largest moves.
• Over 5 years, Common Equity stood at $9.6 billion in 2022, then retreated by 9.09% to $8.7 billion in 2023, then fell by 24.85% to $6.6 billion in 2024, then gained by 13.46% to $7.5 billion in 2025, then decreased by 3.75% to $7.2 billion in 2026.
• The last three Common Equity figures came in at $7.2 billion (Q2 2026), $6.9 billion (Q1 2026), and $7.5 billion (Q4 2025), per Business Quant data.